Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 238

1.

Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.

Oran B, Wagner JE, DeFor TE, Weisdorf DJ, Brunstein CG.

Biol Blood Marrow Transplant. 2011 Sep;17(9):1327-34. doi: 10.1016/j.bbmt.2011.01.007. Epub 2011 Jan 11.

PMID:
21232621
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.

Majhail NS, Brunstein CG, Tomblyn M, Thomas AJ, Miller JS, Arora M, Kaufman DS, Burns LJ, Slungaard A, McGlave PB, Wagner JE, Weisdorf DJ.

Biol Blood Marrow Transplant. 2008 Mar;14(3):282-9. doi: 10.1016/j.bbmt.2007.12.488.

PMID:
18275894
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.

Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT.

Biol Blood Marrow Transplant. 2013 Jun;19(6):981-7. doi: 10.1016/j.bbmt.2013.03.016. Epub 2013 Apr 2.

PMID:
23562738
[PubMed - indexed for MEDLINE]
4.

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.

Goker H, Ozdemir E, Uz B, Buyukasik Y, Turgut M, Serefhanoglu S, Aksu S, Sayinalp N, Haznedaroglu IC, Tekin F, Karacan Y, Unal S, Eliacik E, Isik A, Ozcebe OI.

Transfus Apher Sci. 2013 Dec;49(3):590-9. doi: 10.1016/j.transci.2013.07.030. Epub 2013 Aug 8.

PMID:
23981652
[PubMed - indexed for MEDLINE]
5.

Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.

Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Lode L, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2013 Jun;19(6):934-9. doi: 10.1016/j.bbmt.2013.03.009. Epub 2013 Mar 21.

PMID:
23523970
[PubMed - indexed for MEDLINE]
6.

Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.

Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, Scott B, Fang M, Wood B, Pagel JM, Baumgart J, Delaney C, Maziarz RT, Sandmaier BM, Estey EH, Appelbaum FR, Storer BE, Deeg HJ.

Biol Blood Marrow Transplant. 2014 Apr;20(4):549-55. doi: 10.1016/j.bbmt.2014.01.009. Epub 2014 Jan 16.

PMID:
24440648
[PubMed - indexed for MEDLINE]
7.

A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.

Satwani P, Bhatia M, Garvin JH Jr, George D, Dela Cruz F, Le Gall J, Jin Z, Schwartz J, Duffy D, van de Ven C, Foley S, Hawks R, Morris E, Baxter-Lowe LA, Cairo MS.

Biol Blood Marrow Transplant. 2012 Feb;18(2):324-9. doi: 10.1016/j.bbmt.2011.11.007. Epub 2011 Nov 9.

PMID:
22079471
[PubMed - indexed for MEDLINE]
8.

Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.

Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M.

Biol Blood Marrow Transplant. 2012 Nov;18(11):1727-33. doi: 10.1016/j.bbmt.2012.06.014. Epub 2012 Jul 2.

PMID:
22766220
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.

J Clin Oncol. 2008 Feb 1;26(4):577-84. Epub 2007 Dec 17.

PMID:
18086801
[PubMed - indexed for MEDLINE]
Free Article
10.

Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Nagler A, Labopin M, Shimoni A, Niederwieser D, Mufti GJ, Zander AR, Arnold R, Greinix H, Cornelissen JJ, Jackson GH, Craddock C, Bunjes DW, Ganser A, Russell NH, Kyrcz-Krzemien S, Rocha V, Mohty M.

Biol Blood Marrow Transplant. 2012 Sep;18(9):1422-9. doi: 10.1016/j.bbmt.2012.02.013. Epub 2012 Mar 20.

PMID:
22446014
[PubMed - indexed for MEDLINE]
11.

Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.

Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M, Verneris M, Wagner J, Dusenbery K, Aurora M, Bachanova V, Brunstein C, Burns L, Cooley S, Kaufman D, Majhail NS, McClune B, McGlave P, Miller J, Oran B, Slungaard A, Vercellotti G, Weisdorf DJ.

Biol Blood Marrow Transplant. 2011 Jul;17(7):1025-32. doi: 10.1016/j.bbmt.2010.10.030. Epub 2010 Nov 1.

PMID:
21047561
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.

Huisman C, Meijer E, Petersen EJ, Lokhorst HM, Verdonck LF.

Biol Blood Marrow Transplant. 2008 Feb;14(2):181-6. doi: 10.1016/j.bbmt.2007.09.017. Epub 2007 Dec 31.

PMID:
18215778
[PubMed - indexed for MEDLINE]
13.

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.

Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, Maris MB, Agura ED, Chauncey TR, Wong RM, Forman SJ, Petersen FB, Wade JC, Epner E, Bruno B, Bethge WA, Curtin PT, Maloney DG, Blume KG, Storb RF.

Biol Blood Marrow Transplant. 2008 Feb;14(2):246-55. doi: 10.1016/j.bbmt.2007.11.012.

PMID:
18215785
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.

Grosskreutz C, Ross V, Scigliano E, Fruchtman S, Isola L.

Biol Blood Marrow Transplant. 2003 Jul;9(7):453-9.

PMID:
12869959
[PubMed - indexed for MEDLINE]
15.

Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.

Eom KS, Shin SH, Yoon JH, Yahng SA, Lee SE, Cho BS, Kim YJ, Kim HJ, Min CK, Kim DW, Lee JW, Min WS, Park CW, Lee S.

Am J Hematol. 2013 Aug;88(8):634-41. doi: 10.1002/ajh.23465. Epub 2013 May 30.

PMID:
23620000
[PubMed - indexed for MEDLINE]
16.

Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation.

Brunstein CG, Cantero S, Cao Q, Majhail N, McClune B, Burns LJ, Tomblyn M, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE.

Biol Blood Marrow Transplant. 2009 Feb;15(2):214-22. doi: 10.1016/j.bbmt.2008.11.013.

PMID:
19167681
[PubMed - indexed for MEDLINE]
17.

Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype.

Hemmati PG, Terwey TH, Massenkeil G, le Coutre P, Vuong LG, Neuburger S, Dörken B, Arnold R.

Int J Hematol. 2010 Apr;91(3):436-45. doi: 10.1007/s12185-010-0515-y. Epub 2010 Feb 25.

PMID:
20180052
[PubMed - indexed for MEDLINE]
18.

Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.

Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.

Haematologica. 2002 Jan;87(1):52-8.

PMID:
11801465
[PubMed - indexed for MEDLINE]
Free Article
19.

Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.

Piñana JL, Valcárcel D, Martino R, Barba P, Moreno E, Sureda A, Vega M, Delgado J, Briones J, Brunet S, Sierra J.

Biol Blood Marrow Transplant. 2009 Jan;15(1):21-9. doi: 10.1016/j.bbmt.2008.10.011.

PMID:
19135939
[PubMed - indexed for MEDLINE]
20.

Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities.

Lee SE, Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Kim DW, Lee JW, Park CW, Kim CC.

Int J Hematol. 2010 Sep;92(2):342-50. doi: 10.1007/s12185-010-0649-y. Epub 2010 Aug 10.

PMID:
20694843
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk